Stock Scorecard



Stock Summary for Anavex Life Sciences Corporation (AVXL) - $8.33 as of 11/20/2024 7:47:40 PM EST

Total Score

12 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AVXL

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AVXL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AVXL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AVXL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AVXL (34 out of 90)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0

Latest News for for AVXL

Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? - GameStop ( NYSE:GME ) 11/8/2024 11:28:00 PM
Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 - Anavex Life Sciences ( NASDAQ:AVXL ) 10/31/2024 8:00:00 AM
Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 10/31/2024 8:00:00 AM
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia 10/17/2024 11:30:00 AM
Annovis Bio ( NYSE: ANVS ) to Present at H.C. Wainwright 26th Annual Global Investment Conference 9/5/2024 12:00:00 PM
Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 8/1/2024 11:30:00 AM
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 ( blarcamesine ) in Fragile X Syndrome ( Major Cause of Autism ) at the 19th NFXF International Fragile X Conference - Anavex Life Sciences ( NASDAQ:AVXL ) 7/30/2024 11:30:00 AM
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 ( blarcamesine ) in Fragile X Syndrome ( Major Cause of Autism ) at the 19th NFXF International Fragile X Conference 7/30/2024 11:30:00 AM
Neurodegenerative Disease-Focused Anavex Life Sciences' Alzheimer's Candidate Slows Disease Progression By Almost 39% - Anavex Life Sciences ( NASDAQ:AVXL ) 7/29/2024 12:39:00 PM
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Pitney Bowes ( NYSE:PBI ) 7/29/2024 9:26:00 AM

Financial Details for AVXL

Company Overview

Ticker AVXL
Company Name Anavex Life Sciences Corporation
Country USA
Description Anavex Life Sciences Corp. The company is headquartered in New York, New York.
Sector Name TRADE & SERVICES
Industry Name SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Most Recent Quarter 6/30/2024
Next Earnings Date 11/25/2024

Stock Price History

Last Day Price 8.33
Price 4 Years Ago 5.40
Last Day Price Updated 11/20/2024 7:47:40 PM EST
Last Day Volume 1,475,459
Average Daily Volume 1,240,705
52-Week High 10.45
52-Week Low 3.25
Last Price to 52 Week Low 156.31%

Valuation Measures

Trailing PE N/A
Industry PE 122.49
Sector PE 41.04
5-Year Average PE -17.30
Free Cash Flow Ratio 5.08
Industry Free Cash Flow Ratio 30.25
Sector Free Cash Flow Ratio 94.88
Current Ratio Most Recent Quarter 11.95
Total Cash Per Share 1.64
Book Value Per Share Most Recent Quarter 1.53
Price to Book Ratio 4.87
Industry Price to Book Ratio 5.37
Sector Price to Book Ratio 9.15
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 10.17
Sector Price to Sales Ratio Twelve Trailing Months 2.18
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 84,796,000
Market Capitalization 706,350,680
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 0.99%
Reported EPS 12 Trailing Months -0.51
Reported EPS Past Year -0.38
Reported EPS Prior Year -0.60
Net Income Twelve Trailing Months -41,528,027
Net Income Past Year -47,505,000
Net Income Prior Year -47,978,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 99.44%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 138,756,000
Total Cash Past Year 151,024,000
Total Cash Prior Year 149,157,861
Net Cash Position Most Recent Quarter 138,756,000
Net Cash Position Past Year 151,024,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 141,852,000
Total Stockholder Equity Prior Year 142,491,000
Total Stockholder Equity Most Recent Quarter 129,781,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -30,003,629
Free Cash Flow Per Share Twelve Trailing Months -0.35
Free Cash Flow Past Year 0
Free Cash Flow Prior Year 0

Options

Put/Call Ratio 0.27
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.76
MACD Signal 0.69
20-Day Bollinger Lower Band 4.22
20-Day Bollinger Middle Band 6.17
20-Day Bollinger Upper Band 8.13
Beta 0.60
RSI 54.92
50-Day SMA 5.54
150-Day SMA 8.26
200-Day SMA 10.40

System

Modified 11/20/2024 6:38:18 PM EST